ArticleKidney international reports2026
Biomarker Prediction of Delayed Graft Function and Prognosis Post-Kidney Transplantation.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Aminoacylase-1 (ACY1) and additional biomarkers were evaluated for prediction of delayed graft function (DGF) and prognosis following kidney transplantation. Methods: Serum biomarkers were measured (days 1-2 posttransplant for DGF prediction and 1-3 for prognosis) in 237 patients transplanted in Leeds (2003-2011) in the discovery phase, and 319 patients from 7 UK transplant centers (2012-2016) in the validation phase. Median follow-up was 13.28 years (interquartile range [IQR]: 12.4-13.8) and 9.03 years (IQR: 5.19-10.16), respectively. Results: DGF occurred in 29.5% of discovery cohort patients and 18.2% of validation cohort patients. A DGF linear predictor combining ACY1, soluble tumor necrosis factor receptor-1 (sTNFR1) and cystatin C (CysC) demonstrated an area under the receiver operating characteristic (AUROC) of 0.93, decreasing to 0.83 during validation. Comparable values for the individual components were ACY1 (0.79 vs. 0.65), sTNFR1 (0.88 vs. 0.89), CysC (0.89 vs. 0.82), and 0.75 vs. 0.81 for serum creatinine (Cr) as the gold standard. The linear predictor variables for death-censored graft survival (DCGS) were CysC, ACY1, midkine, and recipient age at transplant, but k-statistic values of 0.55 in all transplants and 0.52 in deceased donor kidney transplants (DDKT) precluded validation. Individually, sTNFR1, CysC, and Cr were significantly associated with DCGS in both the discovery and validation phases. Preliminary findings indicated a consistent association of ACY1 and CysC with DCGS in DDKTs affected by DGF. Impacts of clinical practice changes and biomarker performance across the 2 phases are described. Conclusion: Several biomarkers show potential as predictors of DGF or outcome and should be explored further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.